Lilly 3Q10 3Q10 Revenues: $5.7 billion (+2%) 3Q10 Earnings: $1.3 billion (+38%) YTD Revenues: $16.9 billion (+6%) YTD Earnings: $3.9 billion (+10%) Comments: For the quarter, Zyprexa sales dropped 1% to $1.2 billion, Cymbalta sales were up 4% to $825 million, and Alimta sales rose 21% to $560 million. Strattera sales fell 12% to $128 million. The company faced a number of setbacks during the quarter, including patent invalidations of Strattera and Gemzar (both under appeal), and p...